Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL A randomized phase III study of ramucirumab RAM plus docetaxel DOC vs DOC for second line treatment of stage IV non small cell lung cancer NSCLC


PAZARES L., PEROL M., CIULEANU T., KOWALYSZYN R., RECK M., LEWANSKİ C., ...Daha Fazla

51th Annual Meeting of the American Society of Clinical Oncology, Chicago, Amerika Birleşik Devletleri, 3 - 07 Haziran 2015, cilt.33 identifier

  • Cilt numarası: 33
  • Basıldığı Şehir: Chicago
  • Basıldığı Ülke: Amerika Birleşik Devletleri